|Bid||1.9500 x 900|
|Ask||1.9700 x 800|
|Day's Range||1.8993 - 2.0900|
|52 Week Range||1.7100 - 7.3500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
STANS, SWITZERLAND / ACCESSWIRE / November 1, 2021 / NLS Pharmaceutics Ltd. Since the closing of our initial public offering (IPO) in February, we have moved swiftly into our Phase 2 clinical program for Quilience®, our lead product candidate for the treatment of narcolepsy.
STANS, SWITZERLAND / ACCESSWIRE / October 14, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces preclinical data for NLS-4 (Lauflumide), the Company's next-generation wake-promoting drug candidate, which has shown promise for the treatment of chronic fatigue associated with Long-
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th \- 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The Fall Harvest - Best Ideas from the Buy Side: VIRTUAL begins on Tuesday, October 5th, 2021, with company presentations beginning at 8:30 am Eastern Time.